• Loading stock data…

Concert Pharmaceuticals Completes Enrollment in THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata

[#item_full_content]

Print Friendly, PDF & Email
Spread the word